Pinned Tweet
Today, we announced selection of our lead small molecule #PFM for treatment of hepatobiliary diseases by improving bile composition and enhancing bile flow. We look forward to advancing to first-in-human clinical trials for primary sclerosing cholangitis. bit.ly/48jIezp
We’re sharing translational data on RTY-406 at #TLM26!
These data highlight the dual ABCB4/BSEP MoA and potential to address key drivers of hepatobiliary diseases including PBC and PSC, cholestatic patients with mutations in ABCB4, and PSC.
Learn more: bit.ly/4BH6sCd
96
We’re heading to @AASLDtweets #TLM26! We look forward to presenting translational data on our clinical candidate RTY-406, as a transformative therapy for hepatobiliary diseases, including PSC, PBC, and genetically associated chronic cholestasis.
Read more: bit.ly/3VTqqcx
Thank you @drughunter_com for highlighting our oral ABCB4/BSEP dual positive functional modulator (#PFM) RTY-406, which is in Phase 1 clinical development as a disease-modifying therapy for a number of hepatobiliary diseases including, #PSC. Read here: bit.ly/3VIXxQ8
40
Our VP of Chemistry, Nate Fuller, PhD, presented at #ACSFall2026, highlighting our Positive Functional Modulator (PFM) platform and the discovery and characterization of RTY-406, our clinical asset for primary sclerosing cholangitis (PSC).
Read more here: bit.ly/4cGmdOM
49
We’re heading to #ACSFall2026! Our VP of Chemistry, Nathan Fuller, Ph.D., will present the discovery RTY-406, our clinical candidate, a dual positive functional modulator of ABCB4 & BSEP, which is in development as a new treatment for #PSC.
Learn more: acs.digitellinc.com/live/37/…
1
44
When proteins don't reach the cell surface or function as intended, their activity may be reduced or lost. Our #PFMs are designed to bind wild-type and mutant proteins, improve trafficking to the cell surface, and enhance or restore function.
Learn more: rectifypharma.com/
1
39
Some liver diseases may present with subtle or nonspecific symptoms. Common signs can include persistent itching, fatigue, jaundice, abdominal discomfort, and changes in appetite. Learn about our approach to advancing therapies for hepatobiliary diseases: bit.ly/408DwTh
25
Welcome to the team, Constantine Chinoporos!
As our new Executive Chairman, Constantine brings 30+ years of biopharma leadership to help advance RTY-406 for hepatobiliary diseases, including #PSC and guide Rectify’s next phase of growth.
Read more: bit.ly/3QSg22E
1
1
31
#PSC progresses from inflammation of bile ducts caused by abnormal bile composition which leads to fibrosis & secondary liver damage over time. Understanding bile transporters’ dysfunction, help advance new therapeutic for this severe disease. Learn more: bit.ly/3V5Vul7
21
At the recent #EASLCongress 2026, we shared new preclinical data showing RTY-406 demonstrated significant improvement in a mouse model of primary sclerosing cholangitis (PSC) and proof of mechanism in non-human primates
Check out the data here: bit.ly/4iBujtl
21
What if small molecules could restore protein function instead of simply inhibiting it? Our CSO, Rob Hughes, Ph.D., discussed how positive functional modulators (#PFMs) can unlock new therapeutic opportunities in an interview with @PharmaOnline. Read here: bit.ly/43LVNXd
At #EASLCongress 2026 we are presenting new translational data with our clinical candidate RTY-406 that further supports its potential as a first-in-class disease-modifying treatment for PSC and other hepatobiliary diseases.
Learn more: bit.ly/4wXBm6Y
1
1
157
Heading to #EASLCongress 2026? We look forward to connecting with the global liver community & sharing new preclinical data on RTY-406, our dual ABCB4/BSEP #PFMs candidate in development for #PSC & other hepatobiliary diseases. Learn more: bit.ly/3PCZXgn
Our new publication in Liver International Communications demonstrates how partial loss of ABCB4 function causes toxic bile composition and drives inflammation, fibrosis and liver injury. Read more: bit.ly/48ofBSW
Protein dysfunction frequently underlies the development of serious diseases. At Rectify, we are advancing precision approaches to restore protein function and address underlying drivers of disease.
Learn more: bit.ly/3V5Vul7
1
41
#PrimarySclerosingCholangitis brings daily uncertainty and complex challenges for patients and caregivers. Supporting and advocating for this community is essential. Learn more about our work in #PSC: bit.ly/3V5Vul7
Our CEO, @r_devraj, will join the “Pipeline Prioritization” panel at @LongwoodLeaders #MiamiCEO, convening leaders across the biotech, pharma, academia, regulatory & investment communities to discuss key issues shaping life sciences.
Learn more: bit.ly/425tPFL
1
1
41
In support of #RareDiseaseDay, we stand with the millions affected by rare diseases worldwide. At Rectify, this fuels our commitment to advance science for rare hepatobiliary diseases. Learn more: bit.ly/3IlLQn0
26
Rare hepatobiliary diseases often mean delayed diagnosis, limited options, and daily symptoms that affect quality of life. At Rectify, we are developing #PFMs to restore protein function and address hepatobiliary diseases like #PSC. Learn more: bit.ly/3V5Vul7
32
Our CEO @r_devraj joined The BioHub Podcast to discuss Rectify’s vision for advancing a new class of oral small molecules: our #PFMs. Here, Raj shares how we’re prioritizing unmet medical needs in diseases like #PSC.
Tune in here: bit.ly/3OnU4CN
1
98











